SPRY logo

SPRY
ARS Pharmaceuticals Inc

2,450
Mkt Cap
$797.36M
Volume
1.3M
52W High
$18.90
52W Low
$6.66
PE Ratio
-4.67
SPRY Fundamentals
Price
$8.11
Prev Close
$8.03
Open
$8.08
50D MA
$9.15
Beta
1.25
Avg. Volume
1.62M
EPS (Annual)
-$1.74
P/B
7.05
Rev/Employee
$533,405.06
$1,000.28
Loading...
Loading...
News
all
press releases
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Up 8% - Should You Buy?
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Up 8% - Should You Buy...
MarketBeat·6d ago
News Placeholder
More News
News Placeholder
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 5.7% - Time to Sell?
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 5.7% - Here's What Happened...
MarketBeat·9d ago
News Placeholder
Bamco Inc. NY Buys 1,228,532 Shares of ARS Pharmaceuticals, Inc. $SPRY
Bamco Inc. NY grew its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 3,071.3% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional...
MarketBeat·17d ago
News Placeholder
ARS Pharmaceuticals Q4 Earnings Call Highlights
ARS Pharmaceuticals (NASDAQ:SPRY) executives used the company's fourth-quarter and full-year 2025 earnings call to outline early commercial progress for neffy, its needle-free epinephrine option for...
MarketBeat·23d ago
News Placeholder
ARS Pharmaceuticals: Q4 Earnings Insights
read more...
Benzinga·24d ago
News Placeholder
ARS Pharmaceuticals, Inc. (SPRY) Reports Q4 Loss, Beats Revenue Estimates
ARS Pharmaceuticals, Inc. (SPRY) delivered earnings and revenue surprises of -0.96% and +9.10%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·24d ago
News Placeholder
Exploring ARS Pharmaceuticals's Earnings Expectations
read more...
Benzinga·27d ago
News Placeholder
ARS Pharmaceuticals (SPRY) Expected to Announce Earnings on Monday
ARS Pharmaceuticals (NASDAQ:SPRY) will be releasing its Q4 2025 earnings before the market opens on Monday, March 9. (View Earnings Report at...
MarketBeat·29d ago
News Placeholder
Canadian Natural to Report Q4 Earnings: What's in the Offing?
CNQ gears up to report Q4 earnings as lower price realizations and soft gas weigh on estimates despite record output and strong cash flow.
Zacks·1mo ago
News Placeholder
ARS Pharmaceuticals, Inc. (SPRY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
ARS Pharmaceuticals, Inc. (SPRY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·1mo ago
<
1
2
...
>

Latest SPRY News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.